Literature DB >> 18589296

The importance of high specific radioactivity in the performance of 68Ga-labeled peptide.

Irina Velikyan1, Gerd J Beyer, Elisabeth Bergström-Pettermann, Pernilla Johansen, Mats Bergström, Bengt Långström.   

Abstract

The use of (68)Ga-labeled peptides in diagnosis, dosimetry, therapy planning and follow-up of response to chemo- and radiotherapy requires accurate quantification of tracer binding characteristics in vivo, which may be influenced by the specific radioactivity (SRA) of the tracer. Systematic study of the complexation reaction of DOTA-D-Phe(1)-Tyr(3)-Octreotide (DOTATOC, where DOTA is the chelator 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid) with (67)Ga, (68)Ga, (69,71)Ga and in the presence of competing metal cations [Al(III), Fe(III), In(III)] was performed using conventional and microwave heating techniques and assessed by mass spectrometry. Saturation binding of (68)Ga-DOTATOC to Rhesus monkey brain slices was performed using frozen section autoradiography. High SRA was necessary in order to characterize the saturation binding of (68)Ga-DOTATOC to somatostatin receptors in Rhesus monkey brain sections. The complexation of Ga(III) with DOTATOC suggested more favorable formation compared to Fe(III) and In(III). The microwave heating mode might influence the selectivity of the complexation reaction, especially when comparing the behavior of Ga(III) and In(III). Al(III) was less critical with contamination and could be tolerated up to a concentration equal to that of the peptide bioconjugate. The SRA of (67)Ga-DOTATOC and (67)Ga-NODAGA-TATE (NODAGA-Tyr(3)-Octreotate, where NODAGA is 1,4,7-triazacyclononane-1-glutaric acid-4,7-diacetic acid) exceeded literature data by a factor of 7 and 5-15, respectively. High SRA was critical for providing sufficient contrast and accurate quantification of PET images. Microwave heating mode apart from the acceleration of the labeling reaction also improved the selectivity of the complexation reaction towards gallium. Fe(III) was shown to be the most critical competitor deteriorating the (68)Ga-labeling efficiency.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18589296     DOI: 10.1016/j.nucmedbio.2008.03.002

Source DB:  PubMed          Journal:  Nucl Med Biol        ISSN: 0969-8051            Impact factor:   2.408


  12 in total

Review 1.  Feasibility and availability of ⁶⁸Ga-labelled peptides.

Authors:  Clemens Decristoforo; Roger D Pickett; Alfons Verbruggen
Journal:  Eur J Nucl Med Mol Imaging       Date:  2012-02       Impact factor: 9.236

2.  Positron emission tomographic imaging of copper 64- and gallium 68-labeled chelator conjugates of the somatostatin agonist tyr3-octreotate.

Authors:  Jessie R Nedrow; Alexander G White; Jalpa Modi; Kim Nguyen; Albert J Chang; Carolyn J Anderson
Journal:  Mol Imaging       Date:  2014       Impact factor: 4.488

3.  Development and Evaluation of User-Friendly Single Vial DOTA-Peptide Kit Formulations, Specifically Designed for Radiolabelling with 68Ga from a Tin Dioxide 68Ge/68Ga Generator.

Authors:  Deidré Prince; Daniel Rossouw; Claudia Davids; Sietske Rubow
Journal:  Mol Imaging Biol       Date:  2017-12       Impact factor: 3.488

4.  Preparation and evaluation of a 68Ga-labeled RGD-containing octapeptide for noninvasive imaging of angiogenesis: biodistribution in non-human primate.

Authors:  Irina Velikyan; Örjan Lindhe
Journal:  Am J Nucl Med Mol Imaging       Date:  2018-02-05

5.  Preclinical evaluation of 68Ga-DOTA-minigastrin for the detection of cholecystokinin-2/gastrin receptor-positive tumors.

Authors:  Maarten Brom; Lieke Joosten; Peter Laverman; Wim J G Oyen; Martin Béhé; Martin Gotthardt; Otto C Boerman
Journal:  Mol Imaging       Date:  2011-04       Impact factor: 4.488

6.  Optimal specific radioactivity of anti-HER2 Affibody molecules enables discrimination between xenografts with high and low HER2 expression levels.

Authors:  Vladimir Tolmachev; Helena Wållberg; Mattias Sandström; Monika Hansson; Anders Wennborg; Anna Orlova
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-11-11       Impact factor: 9.236

Review 7.  Recent Advances of Radionuclide-Based Molecular Imaging of Atherosclerosis.

Authors:  Soraya M Kazuma; Deborah Sultan; Yongfeng Zhao; Lisa Detering; Meng You; Hannah P Luehmann; Dulcineia S P Abdalla; Yongjian Liu
Journal:  Curr Pharm Des       Date:  2015       Impact factor: 3.116

8.  In vitro autoradiography of carcinoembryonic antigen in tissue from patients with colorectal cancer using multifunctional antibody TF2 and (67/68Ga)-labeled haptens by pretargeting.

Authors:  Håkan Hall; Irina Velikyan; Elisabeth Blom; Johan Ulin; Azita Monazzam; Lars Påhlman; Patrick Micke; Alkwin Wanders; William McBride; David M Goldenberg; Bengt Långström
Journal:  Am J Nucl Med Mol Imaging       Date:  2012-03-28

Review 9.  Prospective of ⁶⁸Ga-radiopharmaceutical development.

Authors:  Irina Velikyan
Journal:  Theranostics       Date:  2013-12-10       Impact factor: 11.556

10.  Preclinical Assessment of a 68Ga-DOTA-Functionalized Depsipeptide as a Radiodiagnostic Infection Imaging Agent.

Authors:  Thomas Ebenhan; Botshelo Brenda Mokaleng; Jacobus Daniel Venter; Hendrik Gert Kruger; Jan Rijn Zeevaart; Mike Sathekge
Journal:  Molecules       Date:  2017-08-24       Impact factor: 4.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.